TARGET Pediatric AML

Please donate to help save the lives of children with pediatric Acute Myeloid Leukemia (pAML).

Thank you to all of the incredibly generous donors that helped us reach our initial goal to fund a cohort of three patients with pAML into a research study that aims to open a new era of more effective, personalized treatment for pAML patients as a whole!

We are going to keep going so that together we can finally improve the prognosis for children diagnosed with pAML. Our new goal is 100,000 because every child diagnosed with pAML deserves this test!

We will keep you updated as best we can on the progress of this initiative.

Acute Myeloid Leukemia (AML) is a cancer of the bone marrow and blood and is one of the most aggressive forms of childhood cancer. Children with pAML have among the lowest survival rate (64%) of all childhood cancers, as well as a high rate of disease recurrence. Many children with hard to treat AML require a bone marrow transplant, and these children have lower survival rates closer to 50%. Due to the intensity of treatment, children suffer from significant immediate and late effects of therapy that can be fatal or require lifelong care.

There has been very little change in treatment options for children diagnosed with pAML over the past 30 years. pAML now claims more children’s lives than the rest of the leukemias combined. The complexity and severity of pAML requires the development of new, advanced therapies to give children the fighting chance they deserve. It is time to finally advance the treatment of pAML.

Our Goal

To help fund ground-breaking research, diagnostic testing and analysis that will help find more effective treatment solutions allowing children diagnosed with pAML a better chance at survival and bring hope for the future.

New Treatment Option

Whole-Genome Sequencing (WGS) helps to identify clinically significant genetic mutations so that individualized risk assessment and treatment planning can be achieved for children with pAML at diagnosis and relapse.

BC Cancer is at the forefront of utilizing genomics to treat cancer patients. Using the power of WGS to decode and analyze pAML cancer genomes, leading scientific experts will be able to uncover valuable insights about this hard-to-treat cancer.

WGS has the potential to refine, alter, and improve the diagnosis, prognosis, treatment, and management of patients with pAML.

The benefit of this program goes beyond BC, as the shared data informs global research efforts around the world about how mutations cause cancer and what cancer treatment medications are most effective.

This can’t be done without your support!

New research and treatment options are the only way to save the lives of children with pAML. This fundraiser will kick-start a research initiative focused on providing access to genomic analysis for pAML patients in BC that can expand their treatment options and improve their prognosis.

Please donate today.

Thank you for your support.